3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Carcinoma, Hepatocellular
20
Nasopharyngeal Carcinoma
12
Triple Negative Breast Neoplasms
11
Esophageal Neoplasms
11
Stomach Neoplasms
10
Esophageal Squamous Cell Carcinoma
10
Sarcoma
7
Squamous Cell Carcinoma of Head and Neck
6
Lung Neoplasms
6
Uterine Cervical Neoplasms
5
Melanoma
5
Hodgkin Disease
5
Recurrence
4
Colorectal Neoplasms
4
Breast Neoplasms
4
Small Cell Lung Carcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
NSCLC
3
Advanced Gastric Cancer
3
Respiratory Tract Diseases
2
Rectal Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Nasopharyngeal Neoplasms
2
Metastatic Gastric Adenocarcinoma
2
Lymphoma, Extranodal NK-T-Cell
2
Lung Diseases
2
Interventions
Amifostine
4
Cisplatin
3
Voriconazole
2
Radiotherapy
2
Paclitaxel
2
Methotrexate
2
Drug Therapy
2
selinexor
1
sargramostim
1
pazopanib
1
lometrexol
1
icotinib
1
glucarpidase
1
camrelizumab
1
bismuth tripotassium dicitrate
1
apatinib
1
Telbivudine
1
Surgical Procedures, Operative
1
Pregabalin
1
Pharmaceutical Preparations
1
Ofloxacin
1
Nivolumab
1
Metronidazole
1
Levofloxacin
1
Imatinib Mesylate
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gefitinib
1
Folic Acid
1
Etoposide
1
Esomeprazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Drug-Related Side Effects and Adverse Reactions
×
camrelizumab
×
Clear all
NCT04351308
2020-05-19
MAPAC
Peking University People's Hospital
Phase 2
Unknown
60 enrolled